These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19636214)

  • 1. P-wave dispersion in endogenous and exogenous subclinical hyperthyroidism.
    Gen R; Akbay E; Camsari A; Ozcan T
    J Endocrinol Invest; 2010 Feb; 33(2):88-91. PubMed ID: 19636214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of the P wave and P wave dispersion in subclinical hyperthyroidism.
    Cetinarslan B; Akkoyun M; Cantürk Z; Tarkun I; Kahranman G; Komsuoglu B
    Endocr Pract; 2003; 9(3):200-3. PubMed ID: 12917061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of P-wave duration and dispersion in patients with mitral stenosis.
    Guntekin U; Gunes Y; Tuncer M; Gunes A; Sahin M; Simsek H
    Pacing Clin Electrophysiol; 2008 Dec; 31(12):1620-4. PubMed ID: 19067816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antithyroid drugs efficacy on P wave changes in patients with Graves' disease.
    Berker D; Işik S; Canbay A; Aydin Y; Tütüncü Y; Delibaşi T; Güler S
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):298-303. PubMed ID: 19666432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P wave duration and dispersion in patients with hyperthyroidism and the short-term effects of antithyroid treatment.
    Guntekin U; Gunes Y; Simsek H; Tuncer M; Arslan S
    Indian Pacing Electrophysiol J; 2009 Sep; 9(5):251-9. PubMed ID: 19763193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism.
    Aras D; Maden O; Ozdemir O; Aras S; Topaloglu S; Yetkin E; Demir AD; Soylu MO; Erdogan MF; Kisacik HL; Korkmaz S
    Int J Cardiol; 2005 Mar; 99(1):59-64. PubMed ID: 15721500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-wave dispersion and maximum duration are independently associated with insulin resistance in metabolic syndrome.
    Wang W; Zhang F; Xhen J; Chen X; Fu F; Tang M; Chen L
    Ann Endocrinol (Paris); 2014 Jul; 75(3):156-61. PubMed ID: 25016562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism.
    Faber J; Wiinberg N; Schifter S; Mehlsen J
    Eur J Endocrinol; 2001 Oct; 145(4):391-6. PubMed ID: 11580994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observations concerning the natural history of subclinical hyperthyroidism.
    Woeber KA
    Thyroid; 2005 Jul; 15(7):687-91. PubMed ID: 16053385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The influence of subclinical thyroid dysfunction on cardiac hemodynamic and electrophysiological parameters in patients with coronary heart disease and paroxysmal atrial fibrillation].
    Rakhmatullov FK; Klimova SV; Rudakova LE; Pchelinsteva SA; Rakhmatullov AF; Khodakova AI
    Klin Med (Mosk); 2012; 90(10):31-4. PubMed ID: 23285759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial fibrillation associated with exogenous subclinical hyperthyroidism.
    Patanè S; Marte F
    Int J Cardiol; 2010 Nov; 145(2):e57-e59. PubMed ID: 19185932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Autonomy of the thyroid gland: is there an "organ hyperthyroidism" of "euthyroid" patients?].
    Wawrzyn H; Hesch RD
    Med Klin (Munich); 2000 Aug; 95(8):421-8. PubMed ID: 10985062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of short-term propylthiouracil treatment on p wave duration and p wave dispersion in patients with overt hypertyroidism.
    Katircibasi MT; Deniz F; Pamukcu B; Binici S; Atar I
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):376-9. PubMed ID: 17701883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters.
    Goichot B; Caron P; Landron F; Bouée S
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):445-51. PubMed ID: 25959282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only.
    Papi G; Pearce EN; Braverman LE; Betterle C; Roti E
    Am J Med; 2005 Apr; 118(4):349-61. PubMed ID: 15808130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relationship Between Prolidase Activity and Atrial Electromechanical Changes in Patients with Paroxysmal Atrial Fibrillation.
    Tascanov MB
    Comb Chem High Throughput Screen; 2019; 22(1):69-75. PubMed ID: 30843482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism.
    Gencer B; Cappola AR; Rodondi N; Collet TH
    Front Endocrinol (Lausanne); 2021; 12():795492. PubMed ID: 35058884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on subclinical hyperthyroidism.
    Donangelo I; Braunstein GD
    Am Fam Physician; 2011 Apr; 83(8):933-8. PubMed ID: 21524033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid status, cardiovascular risk, and mortality in older adults.
    Cappola AR; Fried LP; Arnold AM; Danese MD; Kuller LH; Burke GL; Tracy RP; Ladenson PW
    JAMA; 2006 Mar; 295(9):1033-41. PubMed ID: 16507804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma.
    Abdulrahman RM; Delgado V; Hoftijzer HC; Ng AC; Ewe SH; Marsan NA; Holman ER; Hovens GC; Corssmit EP; Romijn JA; Bax JJ; Smit JW
    Thyroid; 2011 May; 21(5):471-6. PubMed ID: 21417919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.